[Why patent-protected drugs' cost efficiency should be compared with generic preparations].
Berggren
Fredrik
F
Sjukvårdsavdelningen, Socialstyrelsen.
Lundin
Douglas
D
Ramsberg
Joakim
J
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D016568:Drugs, Generic / Q000191:economics*; D006801:Humans; D010330:Patents as Topic / Q000331:legislation & jurisprudence*
D016568:Drugs, Generic